NFE2L2 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), acquired Nrf2 hotspot mutations demonstrate functional synergy with secondary anaplastic lymphoma kinase (ALK) mutations, conferring therapeutic resistance to second-generation ALK inhibitors [98].